Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions: N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection; Other · Procedure · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 30 Days to 100 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 4
States / cities: New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Depressive Symptoms, Substance Use
Interventions: Arrowhead Business Group Curriculum, Recreational League Control Condition; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 13 Years to 15 Years
Enrollment: 449 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Tuberculosis
Interventions: Higher-Dose Rifampin; Drug
Lead sponsor: Harvard University Faculty of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Retinitis Pigmentosa
Interventions: Sub-Retinal Administration of OCU400-301; Genetic
Lead sponsor: Ocugen; Industry
Eligibility: 3 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Breast Cancer, Tobacco Dependence
Interventions: placebo, varenicline; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions: Episcleral Celecoxib; Drug
Lead sponsor: Targeted Therapy Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Acute Urticaria
Interventions: JDP-205 Injection, Diphenhydramine; Drug
Lead sponsor: JDP Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Traumatic Brain Injury
Interventions: Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI; Drug · Device · Other + 1 more
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis
Interventions: Ensure; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Macular Degeneration
Interventions: 0.5 mg ranibizumab; Drug
Lead sponsor: Charles C Wykoff, PhD, MD; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more

Conditions: Muscle Cramp
Interventions: L-Carnitine, Placebo; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 16 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Los Angeles, California

Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Interventions: CNP-106, Placebo; Drug · Other
Lead sponsor: COUR Pharmaceutical Development Company, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Brea, California • Orange, California + 12 more

Conditions: Uterine Atony, Hypotension
Interventions: Oxytocin Infusion, Oxytocin Bolus; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers, Enteric Hyperoxaluria
Interventions: NOV-001, NB1000S, NB2000P, Placebo; Combination Product · Biological · Drug
Lead sponsor: Novome Biotechnologies Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more

Conditions: Invasive Mould Infection
Interventions: EL219, Active Comparator- IV Antifungal (LAmB or voriconazole); Drug
Lead sponsor: Elion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more

Conditions: Crohn's Disease
Interventions: adalimumab, placebo; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more

Conditions: Chronic Plaque-type Psoriasis
Interventions: CJM112, Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Anniston, Alabama • Anaheim, California • Encino, California + 14 more

Conditions: Psoriasis
Interventions: DFD06; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Madera, California • Santa Ana, California • Hialeah, Florida + 5 more

Conditions: Drug Abuse
Interventions: Istradefylline, Phentermine 45 mg, Placebo; Drug · Other
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Smoking Cessation, Smoking (Tobacco) Addiction
Interventions: chatbot, no chatbot; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Angina Pectoris
Interventions: T89; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more

Conditions: HIV Infections, Pregnancy
Interventions: Anti-HIV Immune Serum Globulin (Human), Globulin, Immune, Zidovudine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 13 Years to 60 Years · Female only
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 48
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 26 more

Conditions: Fatigue
Interventions: Energy Product Placebo Control, Energy Active Product 1; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years and older
Enrollment: 501 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Search by objective public record fields.

Beta-blocker Administration for Cardiomyocyte Division

Evaluation of an Entrepreneurship Program for American-Indian Youth

Trial of High-Dose Rifampin in Patients With TB

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

STOP Heart Disease in Breast Cancer Survivors Trial

Oral Nutritional Optimization in Total Joint Arthroplasty

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

Oral Carnitine for Cramps in Pregnancy

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Oxytocin And Uterotonic Agent Use For Cesarean Delivery

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

A Study to Evaluate Abuse Potential of Istradefylline

PASCAL Feasibility Study

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)

Radicle Energy™ 24_RCA: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes